Clinical Report: A Pharmacologic Off-Switch for Split CARs
Overview
This study introduces a novel drug-regulated off-switch protein–protein interaction (DROP)-CAR system that utilizes venetoclax to reversibly modulate CAR-T cell activation. The findings demonstrate significant receptor disassembly and reduced cytotoxic function in DROP-CAR T cells, highlighting the potential for enhanced safety in CAR-T therapies.
Background
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, yet managing toxicity remains a critical challenge. The ability to control CAR-T cell activity pharmacologically could improve patient safety and treatment outcomes. This study explores a human protein-based system that leverages an existing cancer drug to regulate CAR-T cell function.
Data Highlights
Parameter
Value
Half-maximal inhibitory concentration (IC50) of venetoclax
59 nM
Receptor disassembly half-life
2.8 hours at 1.25 µM
Impact on interferon-γ production
Reduced in DROP-CAR T cells
Duration of in vivo study
22 days
Key Findings
Incorporate specific quantitative results from in vivo studies to enhance completeness.
Clinical Implications
Discuss potential integration of the DROP-CAR system into existing treatment protocols.
Conclusion
The introduction of a pharmacologic off-switch for CAR-T cells using venetoclax represents a significant advancement in the field, offering a practical solution to enhance safety while maintaining therapeutic efficacy.
